A multidisciplinary research team at the University of California, Irvine, has revealed that the circadian clock can be leveraged to enhance the efficacy of checkpoint inhibitor cancer therapy.
The University of Texas MD Anderson Cancer Center and AmMax Bio, Inc. announced a worldwide exclusive license agreement and clinical trial agreement to develop and advance AmMax’s AMB-066 monoclonal antibody therapy as a first-in-class treatment option for patients with colorectal cancer and minimal residual disease as well as those with MRD in other solid tumors.
